CAMBRIDGE, Mass.—Genzyme Corp. said that it has completed a study of Renvela (sevelamer carbonate), which showed a statistically significant reduction of serum phosphorus for hyperphosphatemic patients in chronic kidney disease patients not on dialysis.
Patients in the Renvela study also had a significant reduction in calcium-phosphorus product and in LDL cholesterol, according to Genzyme. The multi-center, single arm, open-label trial included 49 patients at multiple sites in Europe and Australia.
Renvela is a buffered form of Renagel and is intended to control serum phosphorus levels on dialysis patients. Genzyme said Renvela is being developed to replace its existing phosphate binder Renagel. The biopharmaceutical company added that Renvela is a non-calcium, non-metal, non-absorbed phosphate binder that will be available in 800 mg tablets once it is approved.